Biosignatures is an innovative medical informatics company that develops clinical biomarkers to help improve the diagnosis and treatment of disease.
Using their proteomic, statistical and bioinformatics expertise, Biosignatures has developed the Tiger platform to discover and validate novel diagnostic and prognostic biomarkers and develop products that are easy to integrate into everyday clinical practice.
The Tiger platform represents a technical paradigm shift in the development of protein molecular diagnostics, which will lead to the discovery of clinically validated biomarkers in many disease areas.
To date, Biosignatures has used the Tiger platform to discover biomarkers and generate products in four areas where there is a need for clinical tools which can improve patient care:
BiopSave – Prevention of unnecessary biopsies during prostate cancer diagnosis;
TigerPro – Discriminating indolent from aggressive cases of prostate cancer to guide therapy;
BladderSafe – Replacing or supplementing the current bladder cancer diagnostic processes, and;
Renal Check – Identification of patients with renal cancer.